Aberdale brings more than three decades of operational and financial leadership. His track record includes successfully commercializing early-stage ventures to successful exits, as well as executing high-value corporate exits and driving rapid organizational growth.
He joins AiM’s executive leadership team as the company advances its compact, MRI-compatible robotic stereotactic neurosurgery system toward commercial development and regulatory submission.
Worcester, Massachusetts-based AiM develops surgical robotic technology designed to enable surgeons to perform precise neurosurgical procedures directly within an MRI. Its platform leverages real-time intraoperative MRI coupled with robotic guidance in its neurosurgery system. It aims to ensure the precise placement of neurostimulation leads for Parkinson’s disease patients. The platform also extends to a range of cranial procedures like biopsy, tumor ablation and targeted intracranial delivery of novel therapeutics.
The company says its integration enables faster, safer and more accurate procedures while reducing patient risk and healthcare costs. It recently inked a partnership with Siemens Healthineers to combine robotics and MRI technology.
According to the company, Aberdale has spent the past twenty years exclusively within the entrepreneurial ecosystem. During this period, he specialized in taking early-stage startups through commercialization. AiM marks his seventh startup venture. His past includes taking two companies public and orchestrating the private sale of four others.
Commentary from AiM Medical Robotics leadership
Gregory Fischer, founder and CEO of AiM Medical Robotics, said:
“I am thrilled to welcome and work alongside Andy as AiM President and CFO. Andy’s extensive expertise in scaling tech companies, coupled with his proven ability to navigate both public and private capital markets, is exactly what AiM needs as we transition from R&D to commercial development. His leadership will be instrumental in executing our commercial strategy and expanding our strategic partnership ecosystem, including our recent collaboration with Siemens Healthineers.”
Aberdale added:
“AiM’s breakthrough technology has the potential to fundamentally transform the standard of care in neurosurgery, making complex brain procedures faster, safer, and far more precise. I am incredibly excited to partner with Greg, our world-class board, and the entire AiM team. My focus will be on driving operational excellence, building a robust financial foundation, executing on the capital strategies, and driving strategic initiatives necessary to bring this life-changing robotics platform to hospitals and patients globally.”
